BURNABY, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following investor conferences and present a company update when noted:

• Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day on Monday, November 18, 2019;
  
  
• Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 pm ET; and
  
  
• Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:00 pm GMT.

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the on the “Investors” section of Xenon's website at www.xenon-pharma.com. All webcasts will be posted for replay following the event for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.